These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 28751117)

  • 1. Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
    Adam JP; Boumedien F; Letarte N; Provencher D
    Gynecol Oncol; 2017 Oct; 147(1):47-53. PubMed ID: 28751117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
    Ferrandina G; Salutari V; Vincenzi B; Marinaccio M; Naglieri E; Loizzi V; Carpano S; Amadio G; Tonini G; Scambia G; Lorusso D
    Gynecol Oncol; 2013 Sep; 130(3):505-10. PubMed ID: 23774301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.
    McMeekin DS; Lisyanskaya A; Crispens M; Oza AM; Braly P; Doering D; Bayever E; Michiels B; Markman M
    Gynecol Oncol; 2009 Aug; 114(2):288-92. PubMed ID: 19476988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of trabectedin in treating ovarian cancer.
    Teplinsky E; Herzog TJ
    Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
    Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
    Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
    Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trabectedin plus pegylated liposomal doxorubicin (PLD) for patients with platinum-sensitive recurrent ovarian cancer: a prospective, observational, multicenter study.
    Runnebaum IB; Reichert D; Ringsdorf U; Kuther M; Hesse T; Sehouli J; Wimberger P
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1185-1195. PubMed ID: 29623421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer.
    Nicoletto MO; Baldoni A; Casarin A; Randon G; Nardin M; Baretta Z; Lardelli P; Nieto A; Alfaro V; Rigamonti C; Conte PF
    Tumori; 2015; 101(5):506-10. PubMed ID: 26108247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trabectedin for the treatment of relapsed ovarian cancer.
    Papaioannou D; Rafia R; Stevenson MD; Stevens JW; Evans P
    Health Technol Assess; 2011 May; 15 Suppl 1():69-75. PubMed ID: 21609655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens.
    Krasner CN; McMeekin DS; Chan S; Braly PS; Renshaw FG; Kaye S; Provencher DM; Campos S; Gore ME
    Br J Cancer; 2007 Dec; 97(12):1618-24. PubMed ID: 18000504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
    del Campo JM; Sessa C; Krasner CN; Vermorken JB; Colombo N; Kaye S; Gore M; Zintl P; Gómez J; Parekh T; Park YC; McMeekin S
    Med Oncol; 2013 Mar; 30(1):435. PubMed ID: 23397080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.
    López-Guerrero JA; Romero I; Poveda A
    Chin J Cancer; 2015 Jan; 34(1):41-9. PubMed ID: 25556617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
    Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
    Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience.
    Marchetti C; Musella A; Romito A; Vertechy L; Palaia I; Di Donato V; Boccia S; De Felice F; Monti M; Muzii L; Benedetti Panici P
    Oncology; 2017; 93(6):359-366. PubMed ID: 28946142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
    Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
    Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis.
    Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G
    Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer.
    Carter NJ; Keam SJ
    Drugs; 2010 Feb; 70(3):355-76. PubMed ID: 20166769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene.
    Awada A; Cortés J; Martín M; Aftimos P; Oliveira M; López-Tarruella S; Espie M; Lardelli P; Extremera S; Fernández-García EM; Delaloge S
    Clin Breast Cancer; 2016 Oct; 16(5):364-371. PubMed ID: 27266804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.